- Home
- TWFG vs FDMT Comparison
TWFG vs FDMT Comparison
Compare TWFG & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWFG
- FDMT
- Stock Information
- Founded
- TWFG 2001
- FDMT 2013
- Country
- TWFG United States
- FDMT United States
- Employees
- TWFG N/A
- FDMT N/A
- Industry
- TWFG
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- TWFG
- FDMT Health Care
- Exchange
- TWFG NYSE
- FDMT Nasdaq
- Market Cap
- TWFG 484.1M
- FDMT 420.7M
- IPO Year
- TWFG 2024
- FDMT 2020
- Fundamental
- Price
- TWFG $29.23
- FDMT $6.31
- Analyst Decision
- TWFG Buy
- FDMT Buy
- Analyst Count
- TWFG 8
- FDMT 11
- Target Price
- TWFG $31.14
- FDMT $42.80
- AVG Volume (30 Days)
- TWFG 175.4K
- FDMT 1.0M
- Earning Date
- TWFG 02-15-2025
- FDMT 11-13-2024
- Dividend Yield
- TWFG N/A
- FDMT N/A
- EPS Growth
- TWFG N/A
- FDMT N/A
- EPS
- TWFG 0.43
- FDMT N/A
- Revenue
- TWFG $194,211,000.00
- FDMT $17,000.00
- Revenue This Year
- TWFG $19.28
- FDMT N/A
- Revenue Next Year
- TWFG $19.53
- FDMT $87.55
- P/E Ratio
- TWFG $67.98
- FDMT N/A
- Revenue Growth
- TWFG 26.18
- FDMT N/A
- 52 Week Low
- TWFG $21.31
- FDMT $5.58
- 52 Week High
- TWFG $36.50
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- TWFG N/A
- FDMT 36.69
- Support Level
- TWFG N/A
- FDMT $5.58
- Resistance Level
- TWFG N/A
- FDMT $7.58
- Average True Range (ATR)
- TWFG 0.00
- FDMT 0.46
- MACD
- TWFG 0.00
- FDMT -0.06
- Stochastic Oscillator
- TWFG 0.00
- FDMT 34.93
About TWFG TWFG INC
TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.